APA (7th ed.) Citation

A, B., D, S., N, L., CM, P., GB, Z., M, R., & A, B. (2025). Targeted probiotic therapy in irritable bowel syndrome: A clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11. Frontiers in medicine, 12, 1604319. https://doi.org/10.3389/fmed.2025.1604319

Chicago Style (17th ed.) Citation

A, Bertuccioli, Sisti D, Lazzerini N, Palazzi CM, Zonzini GB, Ragazzini M, and Belli A. "Targeted Probiotic Therapy in Irritable Bowel Syndrome: A Clinical Evaluation on Clostridium Butyricum CBM588 and Bifidobacterium Longum W11." Frontiers in Medicine 12 (2025): 1604319. https://doi.org/10.3389/fmed.2025.1604319.

MLA (9th ed.) Citation

A, Bertuccioli, et al. "Targeted Probiotic Therapy in Irritable Bowel Syndrome: A Clinical Evaluation on Clostridium Butyricum CBM588 and Bifidobacterium Longum W11." Frontiers in Medicine, vol. 12, 2025, p. 1604319, https://doi.org/10.3389/fmed.2025.1604319.